Skip to main content

Unlisted Medicines and New Combinations: Verify Before Prescribing

An unlisted medicine should enter a clinic record through a controlled identity-verification process, not by treating typed text as a verified catalogue match. Preserve the original wording, establish the actual ingredients, strength, formulation and route, and make unresolved details visible to the prescriber. Distinguish recording a patient’s reported medicine from issuing a new prescription. A missing search result does not prove that a product is unauthorised, and a familiar brand or available pack does not prove that it is currently appropriate or permitted.

By Bractis · Updated · 15 min read

Indian clinicians and clinic catalogue owners handling unfamiliar brands, specialist formulations and fixed-dose combinations.

Identify why the medicine was not found

An unsuccessful search can reflect a spelling variation, an incomplete catalogue, an unfamiliar brand, a different strength or a product that needs regulatory clarification. These are different problems. Selecting the nearest-looking result may conceal the very discrepancy that needs review.

Record the wording as it was presented and its source: a patient’s recollection, a medicine strip, a specialist prescription or a pharmacy message. Preserve uncertainty about unreadable characters or missing details. A photograph can provide evidence, but a cropped image may omit the strength, manufacturer or formulation.

Ask what the clinic is trying to do with the information. Historical medication reconciliation may need an uncertain reported item while clarification continues. A new prescription requires a clinician to establish what they are actually authorising. One generic “keep as typed” action should not obscure that difference.

Build a medicine identity from evidence rather than a brand prefix

For the actual product, reconcile active ingredients, the amount associated with each ingredient, dosage form, release characteristics, route and relevant manufacturer or brand details. Distinguish strength per tablet or per measured volume from the amount the doctor intends the patient to take.

For a fixed-dose combination, verify every ingredient rather than using the best-known component as the identity. Similar brand families can contain different combinations. A suffix can distinguish a material difference, but its meaning must be established from the actual product information.

If two sources disagree, keep both available while the clinician or appropriate pharmacy professional resolves the discrepancy. Do not overwrite a specialist’s wording with a catalogue guess and then call the result verified. The record should explain which evidence ultimately supported the accepted identity.

Worked case V-63: a strip photograph and a manufacturer page describe different products

Fictional case V-63 concerns an Indian clinic recording a medicine reported at an OPD visit. All product names, ingredient letters, evidence references and times below are invented. At 09:10, the patient reports “Brand L” and says it is a new combination. Here, “new” is the patient’s description; it does not establish a regulatory classification or a verified launch date. No new prescription has been authorised from this report.

At 09:20, a relative forwards front and reverse strip photographs through the family phone. The front appears to show a tablet presentation; the reverse names Ingredient A and Ingredient B, but the amounts and identifying presentation text are cropped. Initially the clinic cannot assume the two images show the same pack. The patient subsequently confirms that they do, which is recorded as a patient statement, not independently proven provenance.

A manufacturer page found at 09:40 describes a liquid under the same fictional brand family with Ingredients A, B and C. This is a substantive mismatch: two listed ingredients on the strip versus three on the webpage, and a tablet versus a liquid. The web page should not supply missing fields for the strip merely because it looks more complete.

The clinic sends the product question, without unnecessary patient details, through a manufacturer contact established independently of the forwarded message. At 10:35, the reply distinguishes the tablet and liquid presentations and says the photographed composition is consistent with the tablet family. It cannot identify the exact strength presentation from the cropped photographs. This narrows the uncertainty; it does not finish verification. The five evidence items remain available with their different limits.

On a narrow screen, scroll the table horizontally to read all columns.

V-63 evidence ledger: what each item establishes and what it cannot settle
Evidence itemInformation availableLimit and next use
E1 — patient report“Brand L”, described by the patient as a new combinationRetain original wording; neither formulation nor regulatory new-drug status is established.
E2 — front photographTablet presentation appears visible; identifying presentation text is incompleteLink to the reported pack with the patient’s stated association; request a complete readable view.
E3 — reverse photographIngredient A and Ingredient B readable; amounts and their basis croppedRecord the visible composition without inventing strengths or concluding that the full identity is verified.
E4 — manufacturer webpageLiquid presentation with Ingredients A, B and CRetain URL and access date as evidence of the mismatch; exclude it as the source for tablet strength.
E5 — manufacturer clarificationDistinguishes the two presentations; photographed composition consistent with tablet familyRetain the actual response and contact provenance; exact strength presentation and physical-pack authenticity remain unconfirmed.

Use different states for reported, verified and prescribable information

The following states are an original workflow model. A clinic may use other labels, but the distinction must remain visible wherever the item appears. An uncertain history entry should not gain prescribing authority merely because it is displayed in the same search menu.

Also distinguish technical mapping from clinical suitability. Identifying a product accurately does not establish that it should be prescribed to this patient or that every potential interaction has been checked.

On a narrow screen, scroll the table horizontally to read all columns.

Handling an unlisted item without manufacturing certainty
StateEvidence availablePermitted next question
Patient-reported wordingA name or description with a recorded sourceWhat additional identity evidence is needed?
Product identity reconciledIngredients, strength and formulation supported by evidenceIs the catalogue mapping accurate and current?
Regulatory question openIdentity known but status or permitted use needs clarificationWhich current authoritative documents address this product?
Clinician-approved prescriptionResponsible prescriber has made the patient-specific decisionDoes the issued document express that exact decision?
Catalogue candidateA proposed reusable entry with source and ownerWho verifies and approves shared reuse?
Superseded or rejected mappingEarlier suggestion was inaccurate or no longer usableWhich drafts or records used it, and what correction is needed?

Use current Indian sources for status questions

CDSCO maintains separate new-drug and FDC/subsequent-new-drug approval listings. Those pages are useful starting points, but a search hit or absence from one dated list is not a complete determination for an individual marketed product. Inspect the relevant documents and obtain qualified clarification where needed.

Status can change after a product was first encountered. For example, the Ministry of Health and Family Welfare announced prohibitions on 16 FDCs in June 2026. This dated example shows why a historical catalogue entry is not sufficient evidence of current status; it is not a substitute for reading the applicable notification.

Keep the conclusion proportional to the source. A notification about a specified combination does not automatically establish a rule about every product containing one of its ingredients. Record the exact formulation, document, date and question being resolved.

Source: CDSCO: Approved New Drugs listings

Source: CDSCO: FDC and Subsequent New Drugs approvals

Source: MoHFW/PIB: Prohibition of 16 FDCs, 20 June 2026

Keep product evidence, regulatory status and permission to reuse separate

V-63 has a useful partial result: the liquid webpage is not an appropriate source for this reported tablet. It still lacks a fully established strength presentation. A catalogue owner should not turn “manufacturer replied” into a single approved label that follows the item into prescriptions, patient history and shared search.

Ask which authority supports each conclusion. A manufacturer can clarify its product descriptions. The relevant regulatory documents and qualified interpretation address the status question within their scope. The prescriber makes the patient-specific decision. The clinic’s catalogue reviewer decides whether a reusable entry satisfies its maintenance process. None of these responsibilities transfers automatically to another person because an email has arrived.

For V-63, no matching regulatory determination has been made. The reviewer keeps the precise question open rather than recording “not in CDSCO, therefore illegal” or “manufacturer website, therefore approved”. Official listings are starting points for a dated, formulation-specific investigation. Search date, document coverage and the actual formulation being compared belong in the review note; a screenshot of a search result is not the conclusion.

On a narrow screen, scroll the table horizontally to read all columns.

V-63 decision map at the fictional 11:00 handover
DecisionState at 11:00Owner and evidence needed to advance
Reported product descriptionTablet family and visible two-ingredient composition supported; strength unresolvedPharmacy reviewer: reconcile a complete pack view with the relevant product information, including amount basis, form, release and route.
Current regulatory questionOpen; no conclusion about the actual productDesignated status reviewer: identify applicable authoritative documents for the exact presentation and record the scope of the conclusion.
Patient-specific prescriptionClinical review accepted but unfinished; no new prescription authorised from V-63Responsible prescriber: assess the patient and uncertainty, then document the actual decision and any communication.
Shared catalogue reuseCandidate held; no new shared entry approvedCatalogue owner: assess verified identity, status evidence, duplicate handling and future maintenance before deciding reuse.

Source: CDSCO: Approved New Drugs listings

Source: CDSCO: FDC and Subsequent New Drugs approvals

Make the prescriber resolve clinically material ambiguity

An interface can allow a doctor to document information without pretending the underlying catalogue entry is verified. It should also make it obvious when structured checks cannot reliably operate on the item. “No warning displayed” is especially weak evidence when ingredients or formulation remain unknown.

The responsible clinician decides the patient plan using appropriate evidence. Reception should not choose an alternative formulation to make the software accept a line. If an immediate clinical decision is needed, obtain qualified assessment rather than allowing a catalogue task to delay necessary care.

The issued prescription must identify the intended medicine and directions clearly enough for the receiving pharmacy and patient. An unresolved search term copied into the final document is not made safer by a neat layout or a signed PDF.

Treat a one-patient entry and a shared catalogue addition as separate decisions

A justified entry in one encounter need not become a global option for every clinician. Shared additions require a source, responsible reviewer, duplicate check and a way to handle later changes. Avoid adding a new public alias for every misspelling encountered at reception.

When an existing catalogue item is the correct match, connect the verified alias through the governed process while retaining the original reported wording in the patient record. Do not rewrite the patient’s history to suggest they originally supplied more precise information than they did.

Write a handover that leaves the unresolved work with an accepted owner

At 10:40, the fictional pharmacy reviewer documents the comparison. The prescriber accepts clinical review at 10:45; the catalogue owner accepts the held candidate at 10:50. At the 11:00 handover, acceptance is recorded, but neither clinical review nor catalogue approval is complete. These times describe this example, not a response-time standard. Clinical need determines whether assessment must happen sooner; the catalogue queue must not determine the patient’s care.

The record below retains five evidence references, one patient-reported item and one held catalogue candidate. There are zero approved shared additions and zero new prescriptions authorised from V-63 at this cutoff. This says nothing about medicines supplied elsewhere or actually taken. Those require their own history and evidence. No dose or real medicine is supplied in this example.

Explain the mismatch neutrally to the patient: “The webpage describes a different presentation from the photographs. The strength information on your strip is not readable yet. Your doctor has accepted review of the medicine question.” This avoids accusing the patient, family, pharmacy or manufacturer of an error that has not been established. Record the language used and whether the patient understood what clarification is being requested; the message itself is not advice to start, stop or substitute treatment.

When a complete image arrives, append it as new evidence and assess what it actually resolves. Do not change the earlier 11:00 note to make verification appear complete at that time. If it reveals another ingredient, a different form or a different pack, reopen the comparison and notify the prescriber who accepted review. A catalogue correction is not proof that the doctor or patient received the revised information.

Trace a corrected identity into the places that used it

If an unlisted entry was later mapped incorrectly, identify affected drafts, issued prescriptions, medication lists and summaries. The clinical response depends on what was actually prescribed, supplied or taken, not just on the catalogue defect.

Preserve the earlier representation and the reason for correction. A silent database replacement can make a subsequent reviewer think the correct ingredient was known at the time. Where copies were supplied externally, use the appropriate correction and communication process.

Do not assume every record containing the alias represents actual exposure. Reconcile the event with the patient and pharmacy where appropriate. A typed historical mention, an unissued draft and a dispensed prescription are different evidence.

Evaluate the workflow with ambiguity rather than a perfect catalogue

Use fictional examples of a spelling variant, two similar formulations, a combination with an omitted ingredient and a patient-reported name that cannot yet be identified. The demonstration should preserve uncertainty without silently converting every entry into a prescribable item.

Then correct one mapping and inspect the audit history and downstream record. A useful system should help the clinic explain what changed and who needs to review it. Search convenience alone does not establish the quality of the catalogue or the prescribing decision.

Worked example: the missing suffix changes the investigation

Fictional case: a patient reports “Brand Q”, while a blurred strip image appears to contain a suffix. Search offers an immediate-release item and a combination product with a similar name. The clinician records the uncertain reported name, obtains a readable source and confirms the actual formulation before deciding the current plan. The clinic maps a verified alias only after catalogue review. It does not select the first result or assume that every previous mention of Brand Q meant the newly identified product. No real medicine or substitution is recommended.

Unlisted Medicine Verification Record

Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.

Use of the information
Are you recording uncertain history, preparing a prescription or proposing a shared catalogue item?
Identity evidence
Which source establishes every ingredient, strength basis, formulation and route?
Open status question
Which current official document or qualified review is needed before drawing a regulatory conclusion?
Correction impact
Where has this wording or mapping already been used, and what requires clinical follow-through?

Questions doctors ask

Does an unlisted medicine mean the product is unauthorised?

No. Search absence may reflect spelling or catalogue coverage. Establish the product identity and consult the relevant current regulatory sources where status is in question; absence from one menu or list is not a complete conclusion.

Is “keep medicine name as typed” enough for a new prescription?

Typed text is not verification. The prescriber needs an adequately established medicine identity and clear patient-specific directions. Uncertain historical information and an authorised prescription should remain distinguishable.

Can a combination product be mapped to its main ingredient?

That would omit potentially important information. Verify all active ingredients and their associated strengths, formulation and route before accepting a structured identity or assessing duplication.

Should every free-text medicine become a shared catalogue entry?

No. A one-encounter record and a reusable catalogue item need separate decisions. Shared additions require verification, duplicate handling, ownership and a maintenance process.

Does the absence of a drug alert mean an unlisted medicine is safe?

An unknown or incompletely mapped item may not be checked reliably. The clinician must know the limits of the information and assess the patient using appropriate evidence rather than treating silence as clearance.

What if the manufacturer website and the medicine strip list different ingredients?

First establish whether they describe the same presentation. Compare the full product name, all ingredients, strength basis, form, release information and relevant pack details. A tablet and a liquid in one brand family may be different products. Retain the discrepancy and seek clarification through a verified contact; do not fill unreadable strip fields from the webpage until that source is shown to apply.

Does a manufacturer’s reply prove that the patient’s physical pack is genuine?

Not automatically. A reply may explain a product description or identify a presentation without authenticating the physical pack, confirming current regulatory status or establishing what the patient took. Record the question asked, evidence supplied and exact scope of the answer. Keep any unresolved authenticity concern distinct from the clinician’s patient-specific assessment.

Sources and scope

Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.

  • CDSCO: Approved New Drugs listings

    Landing page directly checked 28 October 2026: dated new-drug and additional-approval listings. Individual approval PDFs were not assessed in this pass; no particular product is declared approved or unauthorised. V-63 is original fictional operational analysis.

  • CDSCO: FDC and Subsequent New Drugs approvals

    Landing page directly checked 28 October 2026: separate dated FDC and subsequent-new-drug lists. Their linked approval documents were not reviewed for an individual product. The page supports source selection, not a blanket status conclusion from a brand search.

  • MoHFW/PIB: Prohibition of 16 FDCs, 20 June 2026

    Official release directly read 28 October 2026; supports the dated announcement about 16 FDCs. Its linked Gazette was not reviewed in this pass. No individual product assessment, subsequent legal-status determination or actual manufacturer verification is claimed.

Try the workflow
with Bractis.

Bring fictional ambiguous medicine names and inspect how reported wording, verified identity, prescription approval and shared catalogue review remain separate.

Request a clinic demo